Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 155.968$
Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2022-12-02...…
66,000$
-0,90%
Echtzeit-Aktienkurs Biomarin Pharmaceutical Inc.
Bid:
Ask:
Nachrichten zur Biomarin Pharmaceutical Inc. Aktie
Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 731.606$
Mueller, Brian - Vorstand - Tag der Transaktion: 2022-12-02...…
Expert Ratings for Biomarin Pharmaceutical
Latest Ratings for BMRN
DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Nov 2021Credit SuisseMaintainsOutperform Nov 2021Morgan StanleyMaintainsEqual-Weight
View…
Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 531.092$
Mueller, Brian - Vorstand - Tag der Transaktion: 2022-11-23...…
Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?
BioMarin (BMRN) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…
uniQure, BioMarin lead gene therapy stocks higher after regulatory wins
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin stock rises as FDA opts out to hold panel meeting to discuss gene therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin: FDA Drops Plans for AdCom Meeting on Hemophilia A Drug >BMRN
BioMarin: FDA Drops Plans for AdCom Meeting on Hemophilia A Drug >BMRN...…
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA)…
BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled FDA Requests Submission of Upcoming 3-Year Data Analysis from Phase 3…
BioMarin to Participate in Two Upcoming Investor Conferences
Credit Suisse 31st Annual Healthcare Conference 2022: November 8th, 8:35amPT/11:35amET, in Rancho Palos Verdes, CA 13th Annual Jefferies Global Healthcare…
Insiderhandel: Aufsichtsrat kauft Aktien von Biomarin Pharmaceutical im Wert von 314.469$
Alles, Mark J. - Aufsichtsrat - Tag der Transaktion: 2022-10-31...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 129.825$
Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2022-10-31...…
BioMarin Pharmaceutical upgraded to outperform from perform at Oppenheimer
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q BIOMARIN PHARMACEUTICAL For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
Investors were expecting better top-line numbers from the companys earnings report....…
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
BioMarin Pharmaceuticals (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark....…
BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the…
BioMarin GAAP net loss narrows 82% in Q3, but not enough to beat on bottom line
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Recap: Biomarin Pharmaceutical Q3 Earnings
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM.
Here's what investors need to…
Biomarin Pharmaceutical Inc. Q3 Loss decreases, but misses estimates
WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) released Loss for third quarter that decreased from last year but missed the…
Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 26
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Can BioMarin (BMRN) Keep the Earnings Surprise Streak Alive?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…
Insiderhandel: Chief Executive Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 359.560$
Bienaime, Jean Jacques - Vorstand - Tag der Transaktion: 2022-10-14...…
Expert Ratings for Biomarin Pharmaceutical
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Latest Ratings for BMRN
…
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
If approved, BioMarins (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States.…
BioMarin Says FDA Accepts BLA for Hemophilia A Therapy
BioMarin Says FDA Accepts BLA for Hemophilia A Therapy...…
FDA accepts BioMarin BLA for hemophilia A gene therapy
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs…
Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 06
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin redesigns organization, will lay off about 4% of its workforce
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioMarin Reduces About 4% Of Global Workforce
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced a reduction of about 120 employees, or roughly four percent of the…
BioMarin Simplifies Organizational Structure to Increase Efficiency
SAN RAFAEL, Calif., Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization…
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and…
BioMarin Pharmaceutical: Neues Kursziel
St. Louis (www.aktiencheck.de) - Rating-Update:
Paul Matteis, Analyst von Stifel, stuft die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN…